Medicine guide

Selexipag STADA 600 microgram filmomhulde tabletten

As listed in the register: Selexipag STADA 600 microgram filmomhulde tabletten

600 microgram · filmomhulde tablet

  • Prescription only
  • Blood, clotting and anaemia
Active substance
Selexipag
Made by
Stada Arzneimittel AG

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupBlood, clotting and anaemiaB01AC27

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (UPTRAVI). It describes the substance, not this exact product.

Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin.

Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag.

Half-life0.8–2.5 h
Mostly cleared after≈ 8.3 hfive half-lives — our arithmetic
How the body breaks it down

Oxidative metabolism, catalyzed mainly by CYP2C8 and to a smaller extent by CYP3A4, leads to the formation of hydroxylated and dealkylated products.

How it leaves the body

In a study in healthy subjects with radiolabeled selexipag, approximately 93% of radioactive drug material was eliminated in feces and only 12% in urine.

With food

Similar exposures were observed in pediatric study patients after taking whole tablets with water, taking with soft food, and dispersing in apple or orange juice.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-28

Safety of the active substance

From the US prescribing label for the same active substance (UPTRAVI). It describes the substance, not this exact product.

Must not be used by
  • Hypersensitivity to the active substance or to any of the excipients.
  • Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
  • Concomitant use with strong CYP2C8 inhibitors.
  • ( 4, 7.1, 12.3 ) Hypersensitivity to the active substance or to any of the excipients.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byStada Arzneimittel AG
Active substanceSelexipag
Used inBlood, clotting and anaemia
Strength600 microgram
Formfilmomhulde tablet
ClassificationB01AC27 · Blood, clotting and anaemia
Routeoraal gebruik
Dispensing (as stated by the register)Uitsluitend recept
RVG133617

Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician

Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.